Akero Therapeutics Stock Price, News & Analysis

Akero Therapeutics (NASDAQ: AKRO) announced the publication of its Phase 2b SYMMETRY trial results in the New England Journal of Medicine, evaluating efruxifermin (EFX) for treating compensated cirrhosis due to MASH. The 96-week study showed significant fibrosis improvement, with 29% of participants in the EFX 50mg group and 21% in the 28mg group showing improvement compared to 11% in the placebo group.

At week 36, the primary endpoint of ≥1-stage fibrosis improvement without MASH worsening was achieved by 19% and 18% of participants in the 50mg and 28mg groups respectively, versus 13% for placebo. The treatment demonstrated improvements in liver injury markers, insulin sensitivity, and lipid metabolism. Safety profile was consistent with previous trials, with mainly mild to moderate gastrointestinal side effects.

Akero Therapeutics (NASDAQ: AKRO) presented 96-week results from its Phase 2b SYMMETRY trial of efruxifermin (EFX) at EASL Congress 2025. The trial evaluated EFX in patients with compensated cirrhosis caused by MASH. Key findings showed that 39% of patients treated with EFX 50mg demonstrated fibrosis improvement compared to 15% in the placebo group (p=0.009) among patients with baseline and week 96 biopsies. In the intent-to-treat population, 29% of EFX 50mg patients showed improvement versus 11% for placebo (p=0.031). The treatment effect more than doubled from Week 36 to Week 96, highlighting the importance of longer treatment duration. EFX demonstrated efficacy across patient subgroups, including those with type 2 diabetes and those on GLP-1 or statin medications. The safety profile remained consistent with previous trials, with mainly mild to moderate gastrointestinal side effects.

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotech company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 13, 2025, at 1:40 p.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website at www.akerotx.com, where an archived replay will also be available after the presentation.

Akero Therapeutics has announced multiple presentations at the upcoming EASL Congress 2025 in Amsterdam, showcasing research on their drug efruxifermin for treating metabolic diseases. The company will present two oral presentations and one poster focusing on liver disease treatment.

The first oral presentation by Dr. Mazen Noureddin will discuss efruxifermin's impact on fibrosis improvement in patients with compensated cirrhosis due to MASH, based on a 96-week Phase 2b trial (SYMMETRY). The second oral presentation by Prof. Quentin M. Anstee will explore the alignment of non-invasive fibrosis biomarkers with AI-based qFibrosis histology in MASH trials.

Additionally, a poster presentation by Prof. Jörn M. Schattenberg will demonstrate how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study. All presentations will take place between May 7-10, 2025.

Akero Therapeutics (NASDAQ: AKRO) reported significant progress in their Phase 2b SYMMETRY study, demonstrating unprecedented results in treating MASH (Metabolic dysfunction-Associated SteatoHepatitis). The study showed statistically significant reversal of compensated cirrhosis after 96 weeks of treatment with efruxifermin (EFX).

Key highlights include:

• 39% of patients in the 50mg EFX group showed ≥1 stage improvement in fibrosis
• 45% of non-GLP-1 patients experienced cirrhosis reversal
• 70% of patients treated with 50mg EFX showed ≥25% reduction in liver stiffness

The company completed enrollment for Phase 3 SYNCHRONY Real-World Study and expects preliminary results in H1 2026. Financial position remains strong with $797.8 million in cash and equivalents as of December 31, 2024, plus an additional $402.5 million raised in January 2025, providing runway into 2028.

Akero Therapeutics (NASDAQ: AKRO) has successfully closed its upsized public offering, raising approximately $402.5 million in gross proceeds. The offering consisted of two components: 6,427,170 shares of common stock priced at $48.00 per share (including the full exercise of underwriters' option for additional 1,093,750 shares), and 1,958,247 pre-funded warrants at $47.9999 per warrant with a $0.0001 exercise price.

The offering was managed by J.P. Morgan, Morgan Stanley, and Jefferies as joint book-running managers, with UBS Investment Bank acting as co-manager. The securities were offered through an automatically effective shelf registration statement previously filed with the SEC.

Akero Therapeutics (Nasdaq: AKRO) has announced the pricing of an upsized public offering, consisting of 5,333,420 shares of common stock at $48.00 per share and pre-funded warrants to purchase 1,958,247 shares at $47.9999 per warrant. The pre-funded warrants have an exercise price of $0.0001 per share.

The company expects to raise approximately $350.0 million in gross proceeds before deducting underwriting costs and expenses. Akero has granted underwriters a 30-day option to purchase up to an additional 1,093,750 shares. The offering is expected to close around January 30, 2025.

J.P. Morgan, Morgan Stanley, and Jefferies are serving as joint book-running managers, with UBS Investment Bank acting as co-manager for the offering.

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage company focused on metabolic disease treatments, has announced a proposed public offering of $300.0 million of common stock shares. The company plans to grant underwriters a 30-day option to purchase up to an additional $45.0 million of shares at the public offering price, less underwriting discounts and commissions.

The offering will be managed by J.P. Morgan, Morgan Stanley, and Jefferies as joint book-running managers. The securities will be offered through an automatically effective shelf registration statement previously filed with the SEC. The completion of the offering is subject to market and other conditions, with no guarantee of completion or final terms.

Akero Therapeutics (NASDAQ: AKRO) has announced significant topline results from its Phase 2b SYMMETRY study evaluating efruxifermin (EFX) in patients with compensated cirrhosis due to MASH. The study demonstrated statistically significant reversal of cirrhosis at Week 96:

- Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group showed ≥1 stage improvement in fibrosis with no worsening of MASH, compared to 15% for placebo (24% effect size).

- In the Intent to Treat analysis, 29% of the 50mg EFX group demonstrated improvement, compared to 12% for placebo (17% effect size).

The study revealed stronger results in patients not taking GLP-1 at baseline, with 45% showing cirrhosis reversal in the 50mg group versus 17% for placebo. EFX was generally well-tolerated, with most adverse events being grade 1 or 2 gastrointestinal issues.